Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.53 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.52 |
| ▸ | FEN1 | P39748 | 2/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445482 | 1.00 | GRM4 (0.53) | GRM4ALOX5APFEN1LRRK2PDE10A | |
| SCHEMBL2404642 | 0.91 | GRM4 (0.54) | GRM4ALOX5APFEN1LRRK2 | |
| SCHEMBL2406994 | 0.91 | GRM4 (0.54) | GRM4ALOX5APFEN1LRRK2 | |
| SCHEMBL2404646 | 0.91 | GRM4 (0.54) | GRM4ALOX5APFEN1LRRK2 | |
| SCHEMBL31702258 | 0.88 | ALOX5AP (0.43) | GRM4ALOX5APFEN1PDE10A | |
| SCHEMBL20687907 | 0.88 | ALOX5AP (0.43) | GRM4ALOX5APFEN1PDE10A | |
| SCHEMBL20240553 | 0.85 | ALOX5AP (0.46) | GRM4ALOX5APFEN1LRRK2 | |
| SCHEMBL4967417 | 0.85 | ALOX5AP (0.46) | GRM4ALOX5APFEN1LRRK2 | |
| SCHEMBL20689295 | 0.83 | GRM4 (0.42) | GRM4ALOX5APFEN1LRRK2 | |
| SCHEMBL9574598 | 0.83 | ALOX5AP (0.47) | GRM4ALOX5APFEN1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| CN-111848591-B | HDAC inhibitors and methods of making and using the same | 成都先导药物开发股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11001569-B2 | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-11 | — | — | US | disclosed |
| CN-111848591-A | HDAC inhibitors and methods of making and using the same | 成都先导药物开发股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020216298-A1 | HDAC INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都先导药物开发股份有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| WO-2011104337-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011104337-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | WO | disclosed |
| EP-2331551-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010023181-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010023181-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | GRM4 3679/4885ALOX5AP 3531/4885FEN1 2653/4885 |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, TNK2, CMPK1 | GRM4 3896/4885ALOX5AP 2162/4885FEN1 628/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | GRM4 3679/4885ALOX5AP 3531/4885FEN1 2653/4885 |
| US-11001569-B2 | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | GRM4 4152/4885ALOX5AP 2911/4885FEN1 3087/4885 |
| US-20120128686-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | GRM4 3721/4885ALOX5AP 1795/4885FEN1 461/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | GRM4 3679/4885ALOX5AP 3531/4885FEN1 2653/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | GRM4 3679/4885ALOX5AP 3531/4885FEN1 2653/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | GRM4 3679/4885ALOX5AP 3531/4885FEN1 2653/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | GRM4 3679/4885ALOX5AP 3531/4885FEN1 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.